Upcoming Earnings: Q2 '26
Estimated EPS
-$0.23
Estimated Rev
$12.24M
$ABEO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 down -25.00% YoY • Reported revenue of $8.72M • Abeona Therapeutics Inc. expects current capital resources to fund operations for at least 12 months. The company plans to file an IND for ABO-701 and commence first-in-human studies in the second half of 2027.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.23 | -- | -- | N/A |
Q1 '26 | -$0.34 | -$0.30 | 10.45% | BEAT |
Q4 '25 | -$0.35 | -$0.36 | -2.27% | MISSED |
Q3 '25 | -$0.28 | -$0.10 | 64.54% | BEAT |
Q2 '25 | -$0.39 | $1.71 | 538.46% | BEAT |